Effects of Ethanolic Extract of Schisandra sphenanthera on the Pharmacokinetics of Rosuvastatin in Rats
Qing Sun,Li Li,Quan Zhou
DOI: https://doi.org/10.2147/DDDT.S364234
2022-05-17
Abstract:Qing Sun, 1 Li Li, 1 Quan Zhou 2 1 Department of Pharmacy, Zhejiang Hospital, Hangzhou, People's Republic of China; 2 Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China Correspondence: Quan Zhou, Department of Pharmacy, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Jiefang Road No. 88, Shangcheng District, Hangzhou, 310009, Zhejiang Province, People's Republic of China, Tel +86 571 89713473, Email Li Li, Department of Pharmacy, Zhejiang Hospital, No. 12 Lingyin Road, Hangzhou, 310013, Zhejiang Province, People's Republic of China, Email Purpose: Wuzhi capsule (WZ) is a proprietary Chinese medicine prepared from the ethanolic extract of Schisandra sphenanthera that is commonly used to treat liver injury. Statins are widely used in patients with hyperlipidemia, coronary heart disease, metabolic syndrome, type 2 diabetes mellitus, and nonalcoholic fatty liver disease. Co-administration of statins with WZ is possible in clinical practice. WZ has obvious inhibitory effects on the bioavailability of atorvastatin and simvastatin; however, the drug–herb interactions between WZ and rosuvastatin have not been addressed. We explored the effects of WZ on the pharmacokinetics of rosuvastatin in Sprague-Dawley rats to promote a rational use of statins. Methods: Eighteen male rats were randomly and evenly divided into three groups: control group (gavage feeding of rosuvastatin 10 mg·kg − 1 ), single dose group (gavage feeding of a single dose of WZ 150 mg·kg − 1 followed by rosuvastatin 10 mg·kg − 1 ) and multiple doses group (gavage feeding of WZ 150 mg·kg − 1 for 7 days followed by rosuvastatin 10 mg·kg − 1 on the seventh day). Plasma samples were collected at different times before and after rosuvastatin administration. The other 18 female rats were tested the same way as the male rats. All samples were analyzed by a validated LC-MS/MS method, and the pharmacokinetic parameters were calculated using a non-compartmental model. Results: In both male and female rats, there were no statistically significant differences in rosuvastatin pharmacokinetic parameters between the control group, the single dose group, and the multi-dose group. Conclusion: Acute or long-term intake of WZ had no obvious effect on the pharmacokinetics of rosuvastatin, and therefore rosuvastatin could be used as an alternative to atorvastatin and simvastatin when WZ is clinically required in conjunction with statins. An appropriate pharmacodynamic study is needed to encourage the safe use of this combination. Keywords: herb-drug interaction, hyperlipidemia, metabolic syndrome, pharmacokinetics, rosuvastatin, Wuzhi capsule Wuzhi capsule (WZ) is a preparation derived from the ethanol extract of Schisandra sphenanthera and is widely used in clinical practice in China to protect liver function in patients with chronic hepatitis or liver dysfunction. WZ attenuates liver steatosis and inflammation during the development of nonalcoholic fatty liver disease. 1 Statins are widely used in the secondary and primary prevention of atherosclerotic cardiovascular disease. Furthermore, a meta-analysis showed beneficial effects of statin use in reducing inflammatory markers in patients with metabolic syndrome and related disorders. 2 An exploratory analysis of data from 5 trials showed that rosuvastatin 10 mg was highly effective in comprehensively modifying the lipid profile of patients with high low-density lipoprotein cholesterol and metabolic syndrome. 3 Statins can significantly increase the estimated rate of glomerular filtration, reduce serum creatinine, decrease the level of high-sensitivity C-reactive proteins and decrease the level of blood lipids in the treatment of diabetic nephropathy, thus reducing the inflammatory response and protecting the kidney. 4 Stain therapy has favorable effects in hypercholesterolemic patients with regard to the atherogenic dyslipidemia associated with metabolic syndrome. Rosuvastatin had the most favorable effect on the overall atherogenic lipid profile of metabolic syndrome. 5 Risk reducing statin therapy is recommended for almost all patients with type 2 diabetes mellitus (DM2) at 40 years of age or older regardless of cholesterol level. 6 Clinicians should consider intensifying statin regimens to improve dyslipidemia control in statin-treated patients with DM2. 7 Hepatic adverse effects are the most known adverse effects induced by statins. 8 In approximately 1% of patients, statins cause asymptomatic and dose-related elevations in seru -Abstract Truncated-